NIPH Clinical Trials Search

A domestic Phase I study of DCC-2618 in patients with gastrointestinal stromal tumor (GIST) who are refractory or intolerant to three or more prior therapies

Basic Information

Recruitment status	Pending
Health condition(s) or Problem(s) studied	Gastrointestinal stromal tumor that progressed after anticancer chemotherapy
Date of first enrollment	01/07/2026
Target sample size	10
Countries of recruitment
Study type	Interventional
Intervention(s)	DCC-2618 150 mg, administered orally once daily.

Outcome(s)

Primary Outcome	Safety
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	1. Participants with a histologically confirmed diagnosis of GIST. 2. Participants who are refractory or intolerant to treatment with at least imatinib, sunitinib, and regorafenib. 3. Participants with at least one measurable lesion per the modified Response Evaluation Criteria in Solid Tumors (mRECIST) within 28 days prior to the first administration of the investigational product. 4. Participants with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
Exclude criteria	1. Participants with a concomitant or prior history of severe hypersensitivity reactions to other tyrosine kinase inhibitors. 2. Participants with uncontrolled diabetes mellitus. 3. Participants with a systemic infection requiring treatment.